Oncology Pharma Has Provided Initial Funding to NanoSmart Pharmaceuticals to Conduct Feasibility Studies for Initial Phases of IND-Enabling Activities
31. März 2021 08:00 ET
|
Oncology Pharma, Inc.
SAN FRANCISCO, CA, March 31, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that it has provided the initial financing for the initiation of...
Oncology Pharma Reveals Strategic Plans for Company Growth and Focus
16. März 2021 08:00 ET
|
Oncology Pharma, Inc.
SAN FRANCISCO, CA, March 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Oncology Pharma, Inc. (OTC: ONPH) revealed today the Company’s plans for growth and development of its intellectual property...
Oncology Pharma Extends Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Veterinary Oncology
22. Februar 2021 08:00 ET
|
Oncology Pharma, Inc.
SAN FRANCISCO, CA, Feb. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that it has extended a world-wide Licensing Agreement with NanoSmart...
Oncology Pharma is Pleased to Welcome New Chairman to Its Scientific Advisory Board
16. Februar 2021 08:00 ET
|
Oncology Pharma, Inc.
SAN FRANCISCO, CA, Feb. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that Dr. Henry Smith has accepted the role of Chairman of the...
Oncology Pharma Extends Its Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Human Oncology
03. Februar 2021 08:30 ET
|
Oncology Pharma, Inc.
SAN FRANCISCO, CA, Feb. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that it has extended its Licensing Agreement with NanoSmart...
Oncology Pharma and Kalos Therapeutics Expand Licensing Agreement for Exploring Kalos's Anti-Cancer Lead Drug in Treating COVID-19
06. April 2020 08:00 ET
|
Oncology Pharma, Inc.
SAN FRANCISCO, CA, April 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE ‒ Oncology Pharma, Inc. (OTCPK: ONPH) and Kalos Therapeutics (“Kalos”) announced today that the companies amended the terms of...
CORRECTION: Oncology Pharma Receives LOI for Financing for US$ 38.4M from SCP Investment Partners, Ltd
26. Dezember 2019 22:15 ET
|
Oncology Pharma, Inc.
SAN FRANCISCO, CA, Dec. 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – ONCOLOGY PHARMA, INC. (OTCPK: ONPH) is pleased to announce that it has received a letter of intent dated December 20th to...
Oncology Pharma Receives LOI for Financing for US$ 38.4M from SCP Partners Ltd
23. Dezember 2019 07:00 ET
|
Oncology Pharma, Inc.
SAN FRANCISCO, CA, Dec. 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – ONCOLOGY PHARMA, INC. (OTCPK: ONPH) is pleased to announce that it has received a letter of intent dated December 20th to...
Oncology Pharma Signed a Letter of Intent with Kalos Therapeutics for an Exclusive World-Wide Licence and Co-Devlopent of Its Broad-Spectrum Anti-Cancer Drug, KTH 222
19. August 2019 08:00 ET
|
Oncology Pharma, Inc.
SAN FRANCISCO, CA, Aug. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Oncology Pharma (OTCPK: ONPH) is pleased to announce that it signed a Letter of Intent with Kalos Therapeutics (Phoenix, AZ)...
Oncology Pharma Appoints Stefan Gruenwald (MD. Ph.D) as an Advisor on its Advisory Board
15. Juli 2019 07:30 ET
|
Oncology Pharma, Inc.
SAN FRANCISCO, CA, July 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Oncology Pharma, Inc. (OTCPK: ONPH) is pleased and honored to announce the appointment of Stefan Gruenwald (MD. Ph.D) to its...